NCT00571662 · OUTCOME

Responses to Therapy

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant · Source last updated 2023-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

event-free and overall survival at 12 months

Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort I	68

Event free survival

Values in Percent of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cohort I	52	Not reported	Not reported	Not reported	Not reported

Overall survival

Values in Percent of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Cohort I	59	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

event-free and overall survival at 12 months

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

every 6 mo. up to 2 years

title

Responses to Therapy

type

SECONDARY

unit Of Measure

Percent of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice